Outcome measures in dermatomyositis: quality of life and the patient perspective

Affiliations

¹ Department of Medicine, University of California San Francisco, 1701 Divisadero Street, San Francisco, CA, 94115, U.S.A.
² Department of Dermatology, University of California San Francisco, 1701 Divisadero Street, San Francisco, CA, 94115, U.S.A.

Comment

L T Nicholson et al. Br J Dermatol. 2020 Apr.

. 2020 Apr;182(4):830-831.

doi: 10.1111/bjd.18600. Epub 2019 Nov 8.

¹ Department of Medicine, University of California San Francisco, 1701 Divisadero Street, San Francisco, CA, 94115, U.S.A.
² Department of Dermatology, University of California San Francisco, 1701 Divisadero Street, San Francisco, CA, 94115, U.S.A.

No abstract available

Comment on

Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.
Ahmed S, Chakka S, Concha J, Krain R, Feng R, Werth VP. Ahmed S, et al. Br J Dermatol. 2020 Apr;182(4):949-954. doi: 10.1111/bjd.18223. Epub 2019 Sep 8. Br J Dermatol. 2020. PMID: 31206600 Free PMC article.

1. Hundley JL, Carroll CL, Lang W et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006; 54:217-20.
1. Goreshi R, Chock M, Foering K et al. Quality of life in dermatomyositis. J Am Acad Dermatol 2011; 65:1107-16.
1. Robinson ES, Feng R, Okawa J et al. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br J Dermatol 2015; 172:169-74.
1. Klein RQ, Bangert CA, Costner M et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887-94.
1. Brevard JA, Hurtt M, Horobin J et al. Design considerations for clinical trials using the Cutaneous Dermatomyositis Disease Area and Severity Index as a primary endpoint. J Clin Exp Dermatol Res 2017; 8:1-6.